ELDN compared with IMA: revenue, margins and what each company keeps, and the suppliers and customers both name

ELDNEledon Pharmaceuticals, Inc.

Mkt capRevenueRevenue

IMAImageneBio, Inc.

Mkt capRevenueRevenue

Compare

ELDNEledon Pharmaceuticals, Inc.

IMAImageneBio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ELDN

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±32.7%▼−4.32%×0.13

May 14 '26±20.1%▲+1.80%×0.09

Q1 FY26±15.7%▲+1.05%×0.07

Q3 FY25±32.9%▼−7.95%×0.24

IMA1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+0.70%—

= impliedELDN realized, solidIMA realized, hatchedOne scale, both sides: full bar = 33%× = |realized| ÷ impliedSource: market data

ELDNEledon Pharmaceuticals, Inc.

2.75· pre 2.63· delayed

Mkt cap$225.1MRevenue—

IMAImageneBio, Inc.

4.10· pre 4.10· delayed

Pre-marketNov 2 '26delayed

Mkt cap$46.5MRevenue$800,000Q4 FY25

Compare

Pre-marketNov 2 '26delayed

ELDNEledon Pharmaceuticals, Inc.

IMAImageneBio, Inc.

2.75pre 2.63delayed

Price

4.10pre 4.10delayed

$225.1M

Mkt cap

$46.5M

—

Revenue

$800,000Q4 FY25

ELDN2.75vsIMA4.10Pre-marketNov 2 '26delayed